Bacteraemia in hospitalised patients with malignant blood disorders: A retrospective study of causative agents and their resistance profiles during a 14-year period without antibactrial prophylaxis

Hematology Journal

Volumn 4, Issue 6, 2003, Pages 420-426

  Cherif, Honar ^a   Kronvall, Göran ^a   Björkholm, Magnus ^a   Kalin, Mats ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antimicrobial resistance; Bacteraemia; Epidemiology; Haematological malignancy

Indexed keywords

ACICLOVIR; AMIKACIN; ANTIBIOTIC AGENT; CEFTAZIDIME; CEFUROXIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; FLUCONAZOLE; GENTAMICIN; MEROPENEM; PENICILLIN G; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VALACICLOVIR;

ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTEREMIA; BLOOD DISEASE; CHRONIC LYMPHATIC LEUKEMIA; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DOSE RESPONSE; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRAM POSITIVE COCCI; HEMATOLOGY; HOSPITAL PATIENT; HUMAN; INCIDENCE; KLEBSIELLA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MICROORGANISM; MORBIDITY; MORTALITY; MYELOMA; NEUTROPENIA; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; STENOTROPHOMONAS MALTOPHILIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTEREMIA; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNITY, NATURAL; INCIDENCE; INPATIENTS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0347765762     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200334     Document Type: Article

References (43)

1. Hathorn JW, Lyke K. Empirical treatment of febrile neutropenia: evolution of current therapeutic approaches. Clin Infect Dis 1997; 24 (Suppl 2): S256-S265.
2. Andremont A, Lancar R, An Le N, Hattchouel JM, Baron S, Tavakoli T et al. Secular trends in mortality associated with bloodstream infections in 4268 patients hospitalized in a cancer referral center between 1975 and 1989. Clin Microbiol Infect 1996; 1: 160-167.
3. Viscoli C. The evolution of the empirical management of fever and neutropenia in cancer patients. J Antimicrob Chemother 1998; 41 (Suppl D): 65-80.
4. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
5. Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 1998; 41 (Suppl D): 13-24.
6. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995; 39: 445-452.
7. Herwaldt LA, Geiss M, Kao C, Pfaller MA. The positive predictive value of isolating coagulase-negative staphylococci from blood cultures. Clin Infect Dis 1996; 22: 14-20.
8. Marie JP, Vekhoff A, Pico JL, Guy H, Andremont A, Richet H. Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients. J Antimicrob Chemother 1998; 41 (Suppl D): 57-64.
9. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25: 247-259.
10. Oppenheim BA. The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 1998; 41 (Suppl D): 7-11.
11. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16: 1179-1187.
12. Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996; 23: 795-805.
13. Marchetti O, Calandra T. Infections in neutropenic cancer patients. Lancet 2002; 359: 723-725.
14. Johnsen HE, Bjorkstrand B, Carlson K, Gruber A, Blystad A, Fast A et al. Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous stem cell support. Leukemia Lymphoma 1996; 24: 81-91.
15. Gruber A, Bjorkholm M. [Acute myeloid leukemia. Achievements and challenges in the treatment of adults]. Lakartidningen 1997; 94: 2454-2456, 2459-2460.
16. Oberg G, Killander A, Bjoreman M, Gahrton G, Grimfors G, Gruber A et al. Long-term follow-up of patients > or = 60 yr old with acute myeloid leukaemia treated with intensive chemotherapy. Eur J Haematol 2002; 68: 376-381.
17. Glimelius B, Enblad G, Kalkner M, Gustavsson A, Jakobsson M, Branehog I et al. Treatment of Hodgkin's disease: the Swedish National Care Programme experience. Leukemia Lymphoma 1996; 21: 71-78.
18. Engervall PA, Stiernstedt GT, Gunther GC, Bjorkholm MJ. Trimethoprim-sulfamethoxazole plus amikacin as first-line therapy and imipenem/cilastatin as second empirical therapy in febrile neutropenic patients with hematological disorders. J Chemother 1992; 4: 99-106.
19. Engervall P, Bjorkholm M. Infections in neutropenic patients. II: management. Med Oncol 1996; 13: 63-69.
20. Engervall P, Gunther G, Ljungman P, Lonnqvist B, Hast R, Stiernstedt G et al. Imipenem/cilastatin monotherapy as salvage treatment in febrile neutropenic patients. J Chemother 1996; 8: 382-386.
21. Weinstein MP. Current blood culture methods and systems: clinical concepts, technology, and interpretation of results. Clin Infect Dis 1996; 23: 40-46.
22. Bjorkholm M. Chemoprophylaxis of fungal infections in neutropenic patients. Ann Oncol 1994; 5: 571-574.
23. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002; 94: 3230-3246.
24. Kalin M, Bjorkholm M. [Prophylactic and empirical treatment of mycoses in neutropenic fever. Report and comments on meta-analysis]. Lakartidningen 2001; 98: 1899-1903.
25. Lonnqvist B, Palmblad J, Ljungman P, Grimfors G, Jarnmark M, Lerner R et al. Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden. Support Care Cancer 1993; 1: 139-144.
26. Gunther G, Bjorkholm M, Bjorklind A, Engervall P, Stiernstedt G. Septicemia in patients with hematological disorders and neutropenia. A retrospective study of causative agents and their resistance profile. Scand J Infect Dis 1991; 23: 589-598.
27. Fredlund H, Bjoreman M, Kjellander J, Sjoberg L, Bjorne L, Ohlin AL. A 10-year survey of clinically significant blood culture isolates and antibiotic susceptibilities from adult patients with hematological diseases at a major Swedish hospital. Scand J Infect Dis 1990; 22: 381-391.
28. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Granena A, Gudiol F. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis 1996; 15: 291-296.
29. Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 2002; 34: 1524-1529.
30. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on Gram-positive and resistant bacteria. Clin Infect Dis 1999; 29: 490-494.
31. Jones RN. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis 1999; 29: 495-502.
32. Torell E, Cars O, Olsson-Liljequist B, Hoffman BM, Lindback J, Burman LG. Near absence of vancomycin-resistant enterococci but high carriage rates of quinolone-resistant ampicillin-resistant enterococci among hospitalized patients and nonhospitalized individuals in Sweden. J Clin Microbiol 1999; 37: 3509-3513.
33. Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, Patel R. Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 2002; 34: 1469-1474.
34. Sorberg M, Farra A, Ransjo U, Gardlund B, Rylander M, Wallen L et al. Long-term antibiotic resistance surveillance of Gram-negative pathogens suggests that temporal trends can be used as a resistance warning system. Scand J Infect Dis 2002; 34: 372-378.
35. Klastersky J. Empirical treatment of sepsis in neutropenic patients. Int J Antimicrob Agents 2000; 16: 131-133.
36. Murphy M, Brown AE, Sepkowitz KA, Bernard EM, Kiehn TE, Armstrong D. Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer - is it justified? Clin Infect Dis 1997; 25: 346-348.
37. Ortiz E, Sande MA. Routine use of anaerobic blood cultures: are they still indicated? Am J Med 2000; 108: 445-447.
38. Cockerill III FR, Hughes JG, Vetter EA, Mueller RA, Weaver AL, Ilstrup DM et al. Analysis of 281,797 consecutive blood cultures performed over an eight-year period: trends in microorganisms isolated and the value of anaerobic culture of blood. Clin Infect Dis 1997; 24: 403-418.
39. Laffer RR, Frei R, Widmer AF. [Epidemiology of septicemias in a university hospital over 5 years]. Schweiz Med Wochenschr 2000; 130: 1471-1478.
40. Eggimann P, Glauser MP, Aoun M, Meunier F, Calandra T. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients. J Antimicrob Chemother 1993; 32 (Suppl B): 151-163.
41. Biron P, Fuhrmann C, Cure H, Viens P, Lefebvre D, Thyss A et al. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). J Antimicrob Chemother 1998; 42: 511-518.
42. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 2000; 160: 501-509.
43. Micozzi A, Venditti M, Monaco M, Friedrich A, Taglietti F, Santilli S et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis 2000; 31: 705-711.